

Contents

Foreword *xv*

Acknowledgments *xvii*

- 1 Antibacterial Carbohydrate Vaccines** *1*
Federica Compostella, Laura Morelli, and Luigi Lay
- 1.1 Introduction *1*
- 1.1.1 A Brief History of Vaccines *2*
- 1.2 Carbohydrate-Based Vaccines *5*
- 1.2.1 Mechanism of the Immune Response to Carbohydrate-Based Vaccines *12*
- 1.3 Components of Glycoconjugate Vaccines *15*
- 1.3.1 The Carbohydrate Antigen *16*
- 1.3.2 Linkers for Carbohydrate–Protein Conjugation *19*
- 1.3.3 The Carrier Protein *22*
- 1.3.4 The Adjuvant *24*
- 1.4 Technologies Employed for Production of Glycoconjugate Vaccines *25*
- 1.4.1 Traditional Glycoconjugates *26*
- 1.4.2 Glycoconjugates Based on Synthetic Carbohydrate Antigens *28*
- 1.4.2.1 Site-Selective Protein Conjugation *29*
- 1.4.3 Enzymatic and ChemoEnzymatic Approach *30*
- 1.4.4 Bioengineered Glycoconjugates *31*
- 1.4.5 Nanotechnology-Based Glycoconjugate Vaccines *33*
- 1.4.5.1 Outer Membrane Vesicles (OMVs) and Generalized Modules for Membrane Antigens (GMMA) *33*
- 1.4.5.2 Gold Nanoparticles, Liposomes, and Virus-Like Particles *34*
- 1.4.6 Nonprotein-Based Glycoconjugates *36*
- 1.4.7 Noncovalent Vaccines *36*
- 1.5 Conclusion *37*
- Acknowledgments *38*
- References *39*

2	Antifungal Glycoconjugate Vaccines	57
	<i>Linda del Bino, Maria R. Romano, and Roberto Adamo</i>	
2.1	Human Fungal Infections	57
2.2	Immunity Against Fungal Pathogens	59
2.3	Carbohydrate Antigens in Fungal Cell Wall	60
2.4	Glycoconjugate Vaccines Against <i>Candida albicans/Candida auris</i>	61
2.5	Glycoconjugate Vaccines Against <i>Cryptococcus neoformans</i>	64
2.6	Glycoconjugate Vaccines Against <i>Aspergillus fumigatus</i>	66
2.7	Universal Fungal Polysaccharide Antigens	68
2.8	Conclusions and Future Prospects	68
	References	69
3	Carbohydrate-Based Antiviral Vaccines	73
	<i>Adrián Plata and Alberto Fernández-Tejada</i>	
3.1	Introduction	73
3.2	Human Immunodeficiency Virus	74
3.2.1	Vaccine Constructs Derived from gp120 High-Mannose <i>N</i> -Glycan Cluster	75
3.2.1.1	Surface Oligomannose Cluster-Targeting bnAb: 2G12 Antibody	75
3.2.1.2	Synthesis and Immunological Evaluation of 2G12 Epitope Mimics	76
3.2.2	Vaccine Constructs Derived from gp120 First and Second Variable Loops (V1V2)	81
3.2.2.1	V1V2-Targeting bnAbs	81
3.2.2.2	Synthetic V1V2 <i>N</i> -Glycopeptide Antigens as bnAb Epitope Mimics	81
3.2.3	Vaccine Constructs Derived from gp120 Third Variable Loops (V3)	83
3.2.3.1	V3-Targeting bnAbs	83
3.2.3.2	Synthetic Glycoconjugates and <i>N</i> -glycopeptides as V3-Directed bnAb Epitope Mimics	83
3.2.3.3	Synthetic V3 Glycopeptides as bnAb Epitope Mimics	83
3.3	Influenza A Virus	85
3.3.1	Vaccine Constructs Based on Hemagglutinin (HA)	86
3.3.1.1	Hyperglycosylated HA Vaccines	87
3.3.1.2	α -Gal-Based Vaccine Constructs	87
3.3.2	Vaccine Constructs Based on Neuraminidase (NA)	88
3.3.3	Acetalated Dextran as Adjuvant Carrier	89
3.3.4	Multivalent Constructs as Anti-Influenza Inhibitors	89
3.4	Hepatitis C Virus	90
3.5	Ebola Virus	91
3.5.1	Glycoprotein-Based Vaccines	92
3.5.2	Monoclonal Antibodies and Carbohydrate Antiviral Agents as Therapeutics	92
3.6	SARS-CoV-2 Virus	94
3.6.1	Prospective Vaccine Constructs Based on α -Gal Epitope	94
3.6.2	RBD-Based Constructs for Vaccine Development	95

3.6.3	Saponins as Carbohydrate-Based Adjuvant Candidates for COVID-19 Vaccines	95
3.7	Conclusions and Outlook	96
	Acknowledgments	96
	References	97
4	Bacterial Glycolipid Lipid As and Their Potential as Adjuvants	111
	<i>Atsushi Shimoyama and Koichi Fukase</i>	
4.1	Introduction	111
4.2	Bacterial Glycolipid Lipid A: an Innate Immune Stimulant	113
4.3	Vaccines Containing Natural LPS as Adjuvants	117
4.3.1	Cholera Vaccines	117
4.3.2	<i>Salmonella enterica</i> Serovar Typhi Vaccines	117
4.3.3	Other Vaccines	118
4.4	LPS and Lipid A in the Environment or Fermented Foods as Adjuvants	118
4.5	Synthetic and Semisynthetic Lipid As as Adjuvants	120
4.6	Developing Novel Lipid A Adjuvants	121
4.6.1	Parasitic Bacterial Lipid As	121
4.7	Symbiotic Bacterial Lipid As	123
4.8	Lipid A-Based Self-Adjuvanting Vaccines	125
4.9	Conclusions	127
	References	127
5	Antiadhesive Carbohydrates and Glycomimetics	131
	<i>Jonathan Cramer, Lijuan Pang, and Beat Ernst</i>	
5.1	Introduction	131
5.1.1	Carbohydrate-Protein Interactions in Viral Adhesion to Host Cells	131
5.1.2	Bacterial Adhesins and Antiadhesion Therapy	132
5.1.3	Selected Examples	133
5.2	DC-SIGN-Mediated Viral Adhesion and Entry into Myeloid Cells	133
5.2.1	Introduction	133
5.2.2	DC-SIGN Ligands Employing Natural Carbohydrate Epitopes	136
5.2.2.1	Dendrimers	137
5.2.2.2	Nanoparticles	137
5.2.2.3	Polymers	138
5.2.2.4	Other Multivalent Scaffolds	138
5.2.3	DC-SIGN Ligands Employing Carbohydrate Derivatives or Glycomimetics	139
5.2.4	Conclusion and Perspectives	141
5.3	The Bacterial Adhesin FimH	143
5.3.1	UTIs and FimH	143
5.3.2	FimH CRD	143
5.3.3	FimH Antagonists	145
5.3.4	Conclusion and Perspectives	147

5.4	<i>Pseudomonas aeruginosa</i> Virulence Factors (PA-IL and PA-III)	148
5.4.1	Introduction	148
5.4.2	Mono- and Oligovalent Glycomimetic PL-Ligands	149
5.4.3	Conclusions and Perspectives	152
5.5	General Aspects	152
	References	153
6	Targeting Carbohydrates in Cancer – Analytical and Biotechnological Tools	161
	<i>Henrique O. Duarte, Joana Gomes, and Celso A. Reis</i>	
6.1	Aberrant Protein Glycosylation in Cancer	161
6.2	Detection and Mapping of Carbohydrate-Based Antigens in Human Neoplastic Tissues	164
6.3	Imaging Mass Spectrometry	164
6.4	<i>In Situ</i> Proximity Ligation Assay	166
6.5	Glycan Microarrays	169
6.6	Glycoengineered <i>In Vitro</i> , <i>In Vivo</i> , and <i>Ex Vivo</i> Models	171
6.7	Structural Elucidation of Glycoconjugates: Glycomic and Glycoproteomic Strategies	176
6.8	Concluding Remarks	182
	List of Abbreviations	183
	References	185
7	Carbohydrate-Specific Monoclonal Antibody Therapeutics	201
	<i>Matthew Lohman, Hannah Rowe, and Peter R. Andreana</i>	
7.1	Introduction	201
7.2	Types of Monoclonal Antibodies	202
7.2.1	IgG Antibodies	202
7.2.2	IgM Antibodies	203
7.2.3	ScFv and Fab Fragments	203
7.3	Humanization of Monoclonal Antibodies	204
7.3.1	CDR Grafting	204
7.3.2	Transgenic Animals	204
7.4	Breakthrough Research	205
7.5	mAbs from Preclinical to Clinical Studies	206
7.6	Globo Series	206
7.6.1	Blood Group	206
7.6.2	Mucin-Attached Glycans	207
7.7	New Treatment Options for Neuroblastoma	207
7.7.1	History of Unituxin	208
7.7.2	What is Unituxin?	209
7.7.3	Challenges with Unituxin	211
7.7.4	mAbs Binding to Neuroblastoma	211
7.7.5	Chimeric and Humanized Anti-GD2 Antibodies	212
7.7.6	Naxitamab as a Potential Alternative for High-Risk Patients	212

- 7.7.7 Chimeric Antigen Receptors (CARs) Targeting GD2 213
- 7.8 Summary 214
 - List of Abbreviations 215
 - References 216

- 8 Carbohydrates in Tissue Engineering 223**
Laura Russo and Francesco Nicotra
 - 8.1 Introduction 223
 - 8.2 Biomaterials and Medical Devices: Natural and Synthetic Strategies 224
 - 8.2.1 Carbohydrates as Building Blocks for Medical Device Formulation 224
 - 8.2.1.1 Human Polysaccharides: Glycosaminoglycans (GAGs) and Proteoglycans (PGs) 225
 - 8.2.1.2 Polysaccharides from Plants, Algae, Animal, and Microbial Fermentation 228
 - 8.2.2 Carbohydrates as Signaling Molecules: Opportunities in Tissue Engineering and Regenerative Medicine 233
 - 8.3 Carbohydrates in Animal-Derived Medical Devices: Friends or Foes? 234
 - 8.4 Glycoengineering Application to Regenerative Medicine 235
 - 8.5 Future Opportunities and Major Challenges 237
 - Conflict of Interest 237
 - References 237

- 9 Carbohydrate-Based Therapeutics for Lysosomal Storage Disorders 245**
Camilla Matassini, Francesca Clemente, and Francesca Cardona
 - 9.1 An Introduction to Lysosomal Storage Disorders (LSDs) 245
 - 9.2 Available Treatments for LSDs: The Role of Carbohydrate-Based Therapeutics 248
 - 9.2.1 Enzyme Replacement Therapy (ERT) 250
 - 9.2.2 Substrate Reduction Therapy (SRT) 251
 - 9.2.3 Pharmacological Chaperone Therapy (PCT) 252
 - 9.2.4 Combined ERT/PC Therapy 254
 - 9.3 Mucopolysaccharidoses 254
 - 9.4 Sphingolipidoses 258
 - 9.4.1 Fabry Disease 258
 - 9.4.2 Gaucher Disease 262
 - 9.4.3 Niemann–Pick 267
 - 9.4.4 GM1 Gangliosidosis and Morquio B (β -Gal) 268
 - 9.4.5 GM2 Gangliosidosis (β -Hexosaminidase) 272
 - 9.4.6 Krabbe 275
 - 9.5 Glycogen Storage Disorders 275
 - 9.5.1 Pompe Disease 275
 - 9.6 Glycoproteinoses 277
 - 9.6.1 Fucosidosis 277
 - 9.6.2 α -Mannosidosis 279

- 9.7 Conclusions 279
 - Acknowledgments 282
 - Abbreviations and Acronyms 283
 - References 284

- 10 Carbohydrates and Carbohydrate-Based Therapeutics in Alzheimer's Disease 293**
 - Ana M. Matos, João Barros, and Amélia P. Rauter*
 - 10.1 Introduction 293
 - 10.2 O-GlcNAc Transferase (OGT) and O-GlcNAc Hydrolase (OGA) in Neurodegeneration 295
 - 10.2.1 O-GlcNAc Cycling as a Therapeutic Target Against Alzheimer's Amyloid Plaques and Neurofibrillary Tangles 296
 - 10.2.2 OGA Inhibitors 299
 - 10.2.2.1 PUGNAc 301
 - 10.2.2.2 GlcNAcstatins 305
 - 10.2.2.3 Thiazoline Inhibitors 311
 - 10.3 GalNAc in Neurodegeneration 322
 - 10.4 Chitosan and Derivatives in AD Brain 324
 - 10.5 Cholinesterase Inhibitors 325
 - 10.6 Fyn Kinase Inhibitors 330
 - 10.7 Amyloid Protein-Protein Interaction Inhibitors 334
 - 10.8 Inhibitors of A β o and/or Oxidative Stress-Induced Neurotoxicity 338
 - 10.9 Carbohydrate-Protein Interactions as Potential Therapeutic Targets Against AD 341
 - 10.9.1 Lipid-Raft Gangliosides as Membrane Accumulation Sites for Toxic A β Aggregates 341
 - 10.9.2 The Role of Microglial Cells in A β Brain Clearance 342
 - 10.10 Conclusion 343
 - List of Abbreviations 344
 - Acknowledgments 347
 - References 347

- 11 Carbohydrate-Based Antithrombotics 353**
 - Antonella Bisio, Marco Guerrini, and Annamaria Naggi*
 - 11.1 Introduction 353
 - 11.2 Antithrombotic Drugs 354
 - 11.3 Heparin 354
 - 11.4 Mechanism of Interaction with Coagulation Factors 357
 - 11.4.1 Antithrombin-Mediated Activity 357
 - 11.4.2 Heparin Cofactor II Mediated Activity 360
 - 11.4.3 Additional Factors 360
 - 11.4.4 Adverse Effects of Heparin 360
 - 11.4.4.1 Heparin-Induced Thrombocytopenia 361
 - 11.4.4.2 Osteoporosis 361

11.5	Low Molecular Weight Heparins	361
11.5.1	Ultralow Molecular Weight Heparins	363
11.6	Drugs Based on Natural GAG Mixtures	363
11.6.1	The Role of Dermatan Sulfate	364
11.6.2	Sulodexide	364
11.6.3	Danaparoid	365
11.6.4	Mesoglycan	365
11.7	Defibrotide	366
11.8	Pentosan Polysulfate	367
11.9	Fondaparinux and Related Synthetic Oligosaccharides	367
11.10	Chemoenzymatic Synthesis of Oligosaccharides	369
11.11	Conclusions and Perspectives	369
	Acknowledgment	369
	References	370

Index	381
--------------	-----

